Abstract

PAVON MORAN, Valia; JAIME FAGUNDO, Juan Carlos; AGRAMONTE LLANES, Olga  and  HERNANDEZ RAMIREZ, Porfirio. New strategies in the treatment of chronic myeloid leukemia. Rev Cubana Hematol Inmunol Hemoter [online]. 2007, vol.23, n.1, pp. 0-0. ISSN 1561-2996.

New therapeutic models have been recommended in the last years to be used in patients with chronic myeloid leukemia (CML) resistant or intolerant to Imatinib. Most of the models are based on interventions on specific sites of the signal transmission system that the cells used to send information to the nucleus. One of the strategies that has been incorporated is the use of farnesyl transferase inhibitors. Therapeutic products that may be administered by oral route, due to the small size of their molecules, have already been identified. At present, there are 4 inhibitors in more advanced stages, mainly the R115777 (zarnestra, tipifarnib). The search for other tretament models gave rise to the appearance of new molecules that may be used to treat the cases of resistance or intolerance to Imatinib, such as Desatinib and Dilotinib. Other molecule under experimentation phase is that currently known as PKC 412 (N-benzoylstaurosporine), CGP41251 that is a powerful selective inhibitor of the protein kinase C isoforms . The development of the molecular therapeutics has advanced rapidly and its application to CML has attained very positive results that should increase with the incorporation of the new drugs under study and of those that will certainly emerge in the future

Keywords : CML; Imatinib; farnesyl transferase; Desatinib; Dilotinib.